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Background: Studies of avoidance of exposure to group 1 allergens of the Dermatophagoides group (Der p 1) have
not yielded consistent improvements in adult asthma through avoidance. We explored whether the use of pillow
and bed covers and allergen-avoidance counseling resulted in Der 1-level reduction, as measured by enzyme-linked
immunosorbent assay, and thus improved asthma symptoms in adult patients.
Methods: Twenty-five adult patients with moderate or severe atopic asthma were randomized into intervention
and control groups. Intervention patients slept on pillows and mattresses or futons encased in microfine-fiber covers
and were counseled in allergen avoidance through bedroom cleaning. Control patients received neither special covers
nor counseling. In the period August to October in 2009 (pre-intervention) and 2010 (post-intervention), dust samples
were collected in open Petri dishes placed in bedrooms for 2 weeks and by rapid lifting of dust from bedding and skin
using adhesive tape on the morning of 1 day of Petri dish placement. We examined the associations between changes
in Der 1 level (as measured by enzyme-linked immunosorbent assay) and clinical symptom score, minimum % peak
expiratory flow, and fraction of exhaled nitric oxide.
Results: Der 1 allergen levels on the mattress/futon covers and near the floor of the bedrooms of intervention
patients, but not controls, were lower in 2010 than in 2009. From 2009 to 2010, asthma symptom scores decreased
significantly, and minimum % peak expiratory flow increased significantly, in intervention patients. The fall in Der p 1
concentration was correlated with a reduction in the fraction of exhaled nitric oxide.
Conclusions: Minimization of Der 1 allergen exposure by encasing pillows and mattresses or futons and receiving
counseling on avoiding exposure to indoor allergens improved asthma control in adult patients.
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Exposure of sensitized individuals to allergens, including
those associated with house dust mites (HDMs), cats, and
fungi, is a risk factor for asthma exacerbation or persistence
of asthma symptoms [1-3]. HDMs (i.e., Dermatophagoides
pteronyssinus and Dermatophagoides farinae), are major
indoor allergens that can trigger or exacerbate atopic* Correspondence: n-tsurikisawa@sagamihara-hosp.gr.jp
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distribution, and reproduction in any mediumasthma [1-3]. Asthmatic symptoms [4] and bronchial
hyper-responsiveness [5] are reduced in children with
asthma when exposure to HDMs is minimized by en-
casing mattresses and using special pillow covers. Indi-
vidualized, home-based comprehensive environmental
intervention can decrease levels of exposure to indoor
allergens and reduce asthma-associated morbidity in
children [6]. A 90% reduction in allergen levels is feasible
and is considered appropriate [1]. However, most studies,
including a meta-analysis [7,8], have concluded that redu-
cing levels of exposure to HDMs by using chemical and
physical methods does not improve asthma symptoms,tral Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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bronchial hyper-responsiveness [7-10]. Particularly in
adults, lowering HDM levels does not effectively re-
duce asthma symptoms [5,11-14]. One report found no
clear dose–response relationship between indoor allergen
levels and symptom severity [15].
Many factors influence the relationship between exposure
to HDM allergens and symptom development or exacer-
bation. These include the presence of several different
allergens on HDMs, the interaction of many factors to
enhance the airway inflammatory response, and the ex-
istence of several triggers or enhancers of airway nar-
rowing or the perceived severity of symptoms [2]. Such
factors include cold air, exercise, passive or active ex-
posure to cigarette smoke and bronchial infection [2].
Unsurprisingly, therefore, several reviews have con-
cluded that avoidance of exposure to HDM allergens is
not clinically beneficial for asthma patients and that efforts
to avoid these allergens cannot be recommended as part
of asthma management [7,8,10]. These results showed that
the concentration of D. pteronyssinus allergen 1 (Der p 1)
in mattresses did not decrease after an intervention treat-
ment by using bed covers, or that lung function in terms
of peak expiratory flow (PEF), bronchial hyperresponsive-
ness, asthma symptom score, and asthma medication use
did not change after the concentration of Der p 1 in
mattresses was decreased by intervention treatments.
In most studies, the level of Dermatophagoides mite
group 1 (Der 1) allergens in reservoir dust is measured
by collecting mites from bedding with a vacuum cleaner
and is used as an index of allergen exposure [1,2]. Allergen
levels in dust samples are typically presented as micrograms
of allergen per gram of dust protein. However, allergen
levels in reservoir dust are not necessarily good indicators
of the amounts of allergens inhaled [16,17]. Yasueda
et al. [18] developed a sensitive fluorometric enzyme-
linked immunosorbent assay (ELISA) for detecting Der
p 1 and D. farinae group 1 (Der f 1) allergens and used it to
measure the levels of these components on bedding and
human skin. These values were used as indices of ex-
posure and reduced the sensitivity of detection of Der
1 to 1 pg/mL. Earlier, we showed that the levels of Der
1 allergens collected from bedding and skin by using
adhesive tape were correlated with those collected
from airborne dust through simple dust deposition on
plastic Petri dishes [19].
Inhaled corticosteroids (ICS) are the recommended
first-line therapy for persistent adult asthma of all grades
of severity [20]. In studies of avoidance of mite allergen by
intervention using bed covers, almost all adult patients
with asthma have been receiving ICS treatment [7].
The above-mentioned earlier measures of allergen levels
may not have truly reflected the extent of HDM allergen
exposure, and it remains unknown whether measuringDer 1 levels by using the newer, more sensitive, fluoro-
metric ELISA will reveal that exposure avoidance im-
proves clinical symptoms or lung function in adult
asthmatics. We explored whether reductions in HDM
levels on bedding and in the bedroom, as measured by
fluorometric ELISA, affected asthma control in adult




Between August and October 2009, we recruited 25 adult
asthma patients at the National Hospital Organization,
Sagamihara, National Hospital, Kanagawa, Japan. All
patients suffered from moderate or severe atopic
asthma, as diagnosed by using the criteria of the Ameri-
can Thoracic Society [21]. Asthma severity was assessed
by following the current Global Initiative for Asthma
(GINA) guidelines [20] and graded accordingly as follows:
Step 1, intermittent asthma; Step 2, mildly persistent
asthma; Step 3, moderately persistent asthma; and Step 4,
severely persistent asthma. All patients had atopic asthma
and were sensitized to dust mites, as revealed by measure-
ment of mite-specific IgE. Other allergic conditions exhib-
ited by the patients included allergic rhinitis (which can
worsen asthma [22]), allergic dermatitis (diagnosed as
described in [23],) and allergic conjunctivitis (diagnosed
by using the 2009 criteria of the Japanese Dermatological
Association [24]). Exclusion criteria included the presence
of pulmonary diseases other than asthma (chronic ob-
structive pulmonary disease presenting as pulmonary em-
physema, interstitial pulmonary fibrosis, or bronchiectasis).
Study design
Between 1 August and 31 October 2009, each patient
collected ambient dust samples in open Petri dishes
(plastic, not pre-coated with any protein) (90 × 15 mm;
SH90-15; Asahi Glass Co. Ltd., Tokyo, Japan) [19,25,26]
that had been left in the bedroom for 2 weeks. Patients
also collected bedding and skin dust samples with adhesive
tape (Tegaderm Transparent Dressing 1625WJ; 6 × 7 cm;
3 M Health Care, St Paul, MN) [20] on the morning of
one day in this period before cleaning the bed room. The
patients were randomized into intervention and control
groups. Intervention and control patients were classified
in two groups composed of odd number and even number
in accordance with the highest amount of Der 1 in the
bedroom. During February or March 2010, patients in the
intervention group were counseled one-on-one once for
30 min in regard to methods of allergen avoidance; the
protocol was modified from that of Nishioka et al. [4,27].
In February or March 2010, intervention patients placed
covers made of microfine fibers (Microgard; Yasaka Co.,
Chiba, Japan) over their pillows and futons or mattresses
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mendations were made. First, all family members’ bedding
and futon/mattress covers were to be washed at least
monthly at room temperature. Second, the surfaces of
mattresses or futons of all family members were to be
vacuumed at least weekly with a powerful (>900 W)
appliance. Third, wooden floors or tatami matting were
to be wiped with a wet cloth before being vacuumed.
Fourth, all rooms, including bedrooms, were to be
vacuumed at least weekly. Fifth, all carpets were to be
removed or (if this was not possible) vacuumed with a
powerful appliance at least weekly. Sixth, no stuffed
dolls or soft toys were to be kept in the house. Finally,
no furred pets were kept in the house. Patients in the
control group received neither the special covers nor
any hygiene guidelines. In the 2010 sampling period
from August to October, a researcher confirmed by
interview that all patients in the intervention group
were in fact following most of the seven recommended
practices described above. All patients collected house
dust samples in the period 1 August to 31 October
2010 for follow-up clinical measurement. The start
time of the 2-week interval in which each patient col-
lected the 2010 samples differed by less than 1 month
from the start time of the sampling interval used by
the patient in 2009. Airborne dust was collected in four
plastic Petri dishes. Two were placed side by side on
the bedroom floor and two were placed side by side at
a height of 100 cm above floor level. Both sets of dishes
were placed within 2 m of the bed or futon and left un-
disturbed for 2 weeks before collection. Two adhesive
tapes were used to obtain dust samples from the sur-
face of the center of the futon or mattress microfiber
cover, where the patient’s back would have been posi-
tioned in bed. Similarly, subjects sampled dust on the
skin once, on a morning within the sampling period
when the bedroom was due to be cleaned, by applying
tape to the skin of the right and left neck for a few seconds.
All patients continued taking daily ICS; doses, particle sizes,
and delivery devices were not changed from 1 August 2009
to 31 October 2010. Other medications taken during
the study included long-acting β2 agonists (LABAs),
leukotriene receptor antagonists (LTRAs), and long-acting
muscarinic antagonists (LAMAs). Clinical symptoms were
assessed and used to derive total clinical scores. We
documented the presence of cough, sputum production,
wheezing, dyspnea caused by an asthma attack, sneezing
or nasal discharge attributable to exposure to mites, use
of short-acting β stimulants, and emergency hospital
visits for asthma treatment for whole period from August 1
to October 31 each year. Symptoms were scored as follows:
0, no occurrence within a month; 1, some occurrences
(more than one a month but fewer than two a week);
and 2, frequent occurrences (more than once a week).Our hospital ethics committee approved the study. All
relevant tenets of the Helsinki Declaration were followed.
Written informed consent was obtained from each patient.
The study was supported by Health and Labor Science
Research Grants for Research on Allergic Disease and
Immunology, awarded by the Ministry of Health, Labor,
and Welfare of Japan.
Measurement of peak expiratory flow
Patients measured PEF three times every morning and
evening before bronchodilator use during the 2-week
dust collection period each year with an ASSESS PEF
meter (CHEST, Tokyo, Japan) [20]; measurements with
an error of less than 10% variance among PEF measured
three times were recorded by the patient in a diary. After
collecting the patients’ diaries we noted the minimum
pre-bronchodilator PEF level (as a percentage of the pre-
dicted value) obtained within each 2-week test period.
Measurement of exhaled nitric oxide
NO was measured only once in each test period, on the
day on which the Petri dishes were placed in the bedroom.
Exhaled air was collected in a Sievers bag that formed part
of an NO collection kit (Tsuburai et al. [28]). Each subject
took a deep breath of room air through the NO-scavenging
filter and exhaled through a mouthpiece with a flow rate of
70 mL/s against an expiratory resistance of 10 cm H2O.
Five seconds later, the exhaled air was collected into the
1.5-L Mylar bag from the kit. This air was stored at room
temperature and the NO concentration measured within
12 h. Air was drawn out of each bag at 200 mL/min into
an NO chemiluminescence analyzer (NOA model 280A;
Sievers Instruments, Boulder CO) that had a response
time of 200 ms. The fraction of expired NO (FeNO) mea-
sured by this method was within 80% of that measured by
using direct methods [28].
Eosinophil levels in peripheral blood
We quantified eosinophils and white blood cells (WBCs)
in the peripheral blood of all patients by hemocytome-
try at first hospital visit and at study entry before the
intervention.
Measurement of total IgE, DER F-specific IgE, and
DER P 1–specific IgE
Several enzymatic assays employing anti-immunoglobulin
E (IgE) antibodies have supplanted the radioallergosorbent
test (RAST) [29]. Total IgE levels in serum (IU/mL) were
measured by using a radioimmunosorbent test (RIST).
Der f–specific IgE (IU/mL) was measured by using crude
mite allergen and a RAST that featured the use of ELISA; a
nephelometric method was employed (BN II; Dade Behring
Inc., Deerfield, IL) [30]. Der p 1–specific IgE levels
(UA/mL) were measured with component allergen made
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(Pharmacia, Uppsala, Sweden).
Measurement of DER 1 levels
Airborne dust that had settled in the Petri dishes was
suspended in 1 mL of phosphate-buffered saline (PBS)
with 0.05% (v/v) Tween 20, 0.2% (w/v) bovine serum
albumin (BSA), and 0.1% (w/v) sodium azide and then
stored at 4°C until analysis of Der p 1 or Der f 1 levels [25].
Samples on adhesive tapes were placed on paper tissue
(one sample per tissue) (Kimwipe S-200; Crecia, Tokyo,
Japan), placed into polystyrene tubes (10 × 70 mm),
and extracted with 2 mL of PBS containing 0.2% (v/v)
Tween 20, 0.2% (w/v) BSA, and 0.05% (w/v) sodium
azide (PBS-T-BSA) by orbital rotation overnight at room
temperature. Dust samples on adhesive tapes at 1:100 w/v
(20 mg in 2 mL of PBS-T-BSA) were extracted for 4 h at
room temperature. Der p 1 or Der f 1 was quantified by
using the fluorometric ELISA developed by Yasueda et al.
[18]. Polystyrene microplates were coated for 30 min at
37°C with 200 ng of anti-Der p 1 or anti-Der f 1 monoclo-
nal antibody (P1A03), prepared as described by Yasueda
et al. [31]. The plates were incubated overnight at 25°C
with 5 ng of biotinylated rabbit anti-Der p 1 or anti-Der f
1 in 100 μL of PBS-T-BSA containing 1 mg/mL normal
rabbit γ-globulin. After termination of the reaction with
glycin–NaOH, the fluorescence intensity was read with a
microplate fluorescence reader (Spectra Fluor; TECAN
GmbH, Salzburg, Austria). The excitation wavelength was
360 nm and the emission wavelength 465 nm [18]. Results
were expressed as nanograms of allergen per square
meter. The Der p 1 or Der f 1 detection limit was 1 pg/mL
[18]. Der 1 level was calculated as the total amount Der p 1
and Der f 1.
Statistical analysis
All values are expressed as means ± 1 SD (with ranges),
unless otherwise specified. Statistical comparisons among
groups were achieved by using two-way analysis of variance
(ANOVA) with a repeated-measures algorithm, followed by
post-hoc comparisons using the Newman-Keuls test. The
mean values obtained by this process were compared by
using the Wilcoxon matched-pairs T-test. Correlation co-
efficients were obtained by using Spearman’s rank correl-
ation test. P values of <0.05 were considered statistically
significant. Statistical analysis was performed with SPSS for
Windows, version 20 (SPSS Inc., Chicago, IL).
Results
The two groups did not differ significantly in terms of age
at entry into the study, sex ratio, age of onset of asthma,
duration of asthma, severity of asthma, atopy status, or
presence of other atopic disease. All patients were treated
with ICS. The groups did not differ significantly in use ofthe medications LABA, LTRA, LAMA, or theophylline
(Table 1). Patients in the intervention group washed their
bedding or futon covers, cleaned their mattresses or futons,
and wiped surfaces with wet towels before vacuuming more
significantly frequently than did controls (data not shown).
In the intervention group, one patient kept a cat and three
kept dogs; in the control group two kept cats and one kept
a dog. No significant between-group differences were evi-
dent in terms of serum IgE level (measured by using RIST),
IgE RAST for Der f 1, or eosinophil count, either at the
time of the first hospital visit or at the time of study entry
(Table 2). The eosinophil count in both groups was not
higher than the normal range (less than 6% of WBCs). The
levels of Der 1 allergen collected from the futon/mattress
covers by using tape (Figure 1(a); P < 0.01) and from Petri
dishes placed on the floor in the bedrooms (Figure 1(b);
P < 0.01) were significantly lower after intervention; the
levels did not differ significantly between pre- and post-
intervention in the control group. The levels of Der 1 aller-
gen on the skin tape (data not shown) and in Petri dishes
placed 100 cm above the bedroom floor (Figure 1(c)) did
not change in either group. The levels of Der 1 on the
futon/mattress covers or on skin samples taken with adhe-
sive tape were each significantly correlated with those in
the Petri dishes on the floor or 100 cm high (P < 0.01; data
not shown). The clinical symptom score at the time of assay
of Der 1 allergen levels in patients in the intervention group
fell after the 2010 intervention (Figure 2(a); P < 0.01). The
minimum % PEF value in patients in the intervention group
increased in 2010 after intervention (Figure 2(b); P < 0.05).
Neither the clinical symptom score nor the % PEF value
differed between 2009 and 2010 in the control patients
(Figure 2). FeNO levels did not change between 2009 and
2010 in either group (data not shown). In all patients, the
change in Der 1 level in the bedroom in the Petri dishes on
the floor between the time of study entry (2009) and the same
time in 2010 was inversely correlated with the change in
minimum % PEF (P < 0.01) (Figure 3(a)) and positively corre-
lated with the change in FeNO level (P < 0.05) (Figure 3(b)).
However, the change between 2009 and 2010 in Der 1 levels
on adhesive tape samples from the skin or bedding was not
correlated with the change in minimum % PEF or FeNO
level (data not shown). In the intervention group in 2010,
Der 1 levels on tape samples from the futon/mattress covers
of 10 of 16 patients (Figure 4(a)) (P = 0.16) and in the bed-
room air of 10 of 14 patients (Figure 4(b)) (P < 0.05) fell to
lower than the levels before intervention. The levels of Der
p 1–specific IgE decreased in patients in both the inter-
vention (Figure 5(a)) (P < 0.05) and control (Figure 5(b))
(P < 0.01) groups between 2009 and 2010.
Discussion
Levels of Der 1 allergen exposure were decreased in adult
patients by encasing pillows and mattresses or futons and
Table 1 Baseline data on the intervention and control groups
Intervention group N = 13 Control group N = 12 P-value
Age (years) at time of study entry; mean ± SD 47.8 ± 11.0 46.5 ± 16.1 NS1
Sex (M/F) 5/8 4/8 NS2
Atopic rhinitis (yes/no) 9/4 9/3 NS2
Atopic conjunctivitis (yes/no) 7/6 10/2 NS2
Atopic dermatitis (yes/no) 4/9 5/7 NS2
Age at onset of asthma (years); mean ± SD 23.4 ± 19.7 35.5 ± 17.0 NS1
Duration of asthma (from time of onset to time of study entry) (years) 25.2 ± 19.9 12.3 ± 13.7 NS1
Step 1/2/3/4 asthma severity* 0/2/4/7 0/3/5/4 NS2
Daily dose of ICS (μg; converted to CFC-BDP equivalents) 753.8 ± 489.2 566.7 ± 302.5 NS1
Use of LABA; n (%) 8 (61.5) 7 (58.3) NS2
Use of LTRA; n (%) 6 (46.2) 5 (41.7) NS2
Use of LAMA; n (%) 2 (15.4) 2 (16.7) NS2
Use of theophylline; n (%) 6 (46.2) 6 (50.0) NS2
Data are presented as means ± SD or means (ranges).
NS, not significant.
1 Two-way ANOVA with repeated measures among the two groups.
2 Chi-squared testing revealed no significant differences between the values of the two groups.
Values of P < 0.05 were considered to be statistically significant.
* According to GINA guidelines.
CFC-BDP, chlorofluorocarbon-propelled beclomethasone dipropionate; LABA, long-acting β2 agonist; LAMA, long-acting muscarinic antagonist; LTRA.
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gens; asthma control was also increased. Factors that
exacerbate asthma in adult patients include not only
exposure to indoor allergens derived from HDMs,
cockroaches, cats, dog, and fungi, but also respiratory
infections [32], development of allergic rhinitis [33],
high levels of airborne pollutants [34,35], changes in
the weather [36], and exercise [37]. No clear evidence
of a dose–response relationship between HDM levels
and asthma severity has yet been found [2].Table 2 Serum IgE and eosinophil levels in peripheral blood a
Intervention group
At first hospital visit
Serum IgE RIST (UA/mL) 1718.9 ± 4164.8
Log serum IgE RIST (UA/mL) 2.61 ± 0.69
Serum IgE RAST for Der f (IU/mL) 25.3 ± 34.0
Log serum IgE RAST for Der f (IU/mL) 1.00 ± 0.72
No. of eosinophils (/μL) 430.7 ± 231.4
At study entry
Serum IgE RIST (UA/mL) 1169.6 ± 1559.9
Log serum IgE RIST (UA/mL) 2.67 ± 0.65
Serum IgE RAST for Der f (IU/mL) 24.7 ± 26.2
Log serum IgE RAST for Der f (IU/mL) 0.95 ± 0.60
No. of eosinophils (/μL) 215.6 ± 149.4
Data are presented as means ± SD.
NS, not significant.
1 Two-way ANOVA with repeated measures among two groups.
Values of P < 0.05 were considered statistically significant.Cockroach allergen (Bla g 1) levels greater than 8 U/g
dust are associated with asthma exacerbation. Cockroach
allergen avoidance by cleaning, vacuuming, dishes, and
sealing food does not reduce asthma exacerbation
related to the levels cockroach allergen. Similarly,
there is no relationship between cat allergen (Fel d 1)
sensitization or symptoms and the current level of cat
allergen in the home. Moreover, cat allergen levels in
the home for several years are maintained after the cat
has been removed [2].t the first hospital visit and at study entry
N = 13 Control group N = 12 P-value
928.6 ± 1258.0 NS1
2.57 ± 0.66 NS1
28.9 ± 41.4 NS1
0.95 ± 0.75 NS1
437.4 ± 315.5 NS1
589.3 ± 640.0 NS1
2.57 ± 0.45 NS1
33.9 ± 48.1 NS1
0.89 ± 1.00 NS1
















on floor at 100 cm above floor
Figure 1 Der 1 allergen levels (a) on tape samples from futon or mattress covers, (b) in Petri dish samples from the bedroom floor,
and (c) in Petri dish samples from the bedroom 100 cm above the floor, for patients in the intervention group before intervention
(in 2009) and 1 year later (after intervention), and in the non-intervention group during the same test periods. Mean values were
compared by using the Wilcoxon matched-pairs T-test. A P value of <0.05 was considered statistically significant. † P < 0.01; NS: not significant.
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ducing Der 1 levels by covering mattresses or futons
and cleaning thoroughly in the bedroom may improve
the clinical symptoms of asthma [38,39]. In our study,
we confirmed that there was no relationship between
bedroom Petri dish Fel d 1evels and asthma exacerba-
tion in three patients with asthma and cat allergen
sensitivity (data not shown).
Here, we showed that, by avoiding exposure to HDMs






Figure 2 Clinical symptom scores (a) and minimum % PEF values (b)
(in 2009) and 1 year later (after intervention), and in the non-interven
compared with the aid of the Wilcoxon matched-pairs T-test. A P value of
not significant.asthma who were sensitive to HDMs achieved total asthma
control (as defined by the GINA guidelines [20]), unlike
the controls. The levels of Der 1 on the futon or mattress
covers of intervention-group patients did not fall upon
intervention in 2010 after covers made of microfine fibers
were employed, unless these patients followed the direc-
tions for allergen avoidance (Figure 4(a)). Thus for a de-
crease in Der 1 allergen levels the patients needed to not
only encase the pillows and futon or mattress cover but






in patients in the intervention group before intervention
tion group during the same test periods. Mean values were






















Ratio of amount of log Der 1 in
bedroom on floor between before
and after intervention
Ratio of amount of log Der 1 in
bedroom on floor between before
and after intervention
Figure 3 Correlations between log Der 1 ratio and changes in minimum % PEF value (a) and FeNO level (b) in intervention-group patients
before intervention (in 2009) and 1 year later (after intervention), and in the non-intervention group during the same test periods. Each
ratio is [log Der 1 level in 2010 / log Der 1 level in 2009]. The change in minimum % PEF was calculated as (2010% PEF–2009% PEF)/2009% PEF × 100
(%). Each change in FeNO level was calculated as 2010 FeNO value/2009 FeNO value. Twenty-two of the 25 patients recorded their PEF measurements
daily, and 23 of 25 performed FeNO measurements. Correlation coefficients (r values) were obtained by using Spearman’s rank correlation test.
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to indoor allergens has not previously been shown to
be of clinical benefit in adult patients [20]. However,
such an approach effectively controls asthma in children
[40,41]. We found that Der 1 levels in bedrooms were only































Figure 4 Decreases or increases in Der 1 levels on (a) tape samples fr
100 cm above the bedroom floor. The “increase” and “decrease” groups
or fell by more than the 2009 Der 1 levels (intervention group = “With cove
patients, and y-axes show percentages of patients. The chi-squared test wa
groups. A P value of <0.05 indicates statistical significance.bedding covers were used (Figure 4(b)). However, the
small size of our groups may have influenced the sig-
nificance of our findings.
Futon or mattress cover levels of Der 1 (sampled by using
adhesive tape) were significantly correlated with those in































at 100 cm above floor
P<0.05
om futon or mattress covers and (b) Petri dish samples from
respectively include data from patients whose 2010 Der 1 levels rose
r”; control = “Without cover”). Numbers in boxes are numbers of






















Figure 5 Log Der p 1–specific IgE levels in patients in the
intervention group before intervention (in 2009) and 1 year
later (after intervention), and in the non-intervention group
during the same test periods. Der p 1–specific IgE levels (UA/mL)
were measured by using the CAP system (Pharmacia, Uppsala,
Sweden). Mean values were compared by using the Wilcoxon
matched-pairs T-test. A P value of <0.05 was considered statistically
significant. * P < 0.05; † P < 0.01.
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to the intervention group likely contributed to the observed
reduction in Der 1 levels, because the reduced bedroom air
Der 1 level (achieved by applying the recommended clean-
ing protocols and house hygiene) may have been resulted
from the observed reduction in futon or mattress cover
Der 1 concentrations. We surmised that the concentra-
tion of Der 1 rising up into the bedroom air was de-
creased not only by the addition of covers but also by
vacuuming of the futon or mattress and wiping of the
floor with a damp cloth.
Reductions in Der 1 levels on tape samples from futon
or mattress covers and in bedroom air samples collected
from near the floor over the 2 weeks were associated
with improvements in symptom scores and increases in
minimum % PEF levels after intervention. However, in
the control group neither the ambient level of Der 1 al-
lergen nor the clinical score changed between 2009
and 2010. Reducing levels of exposure to HDM aller-
gens reportedly improves forced expiratory volume in
1 s in asthmatic children [42,43]. However, another
study has found that respiratory parameters improve in
some, but not all, adult patients [7,44].
FeNO levels did not change between 2009 and 2010 in
any of the patients (data not shown). We consider that
this was not an artifact caused by the large variation in
FeNO levels measured by using our off-line method.
Because the observed change in FeNO level after inter-
vention was correlated with the change in bedroomDer 1 level. Reduced exposure to Der 1 caused the
FeNO level to fall and the minimum % PEF to improve.
Moreover, the extent of airway eosinophilic inflamma-
tion may have fallen after intervention, as this is reflected
in a drop in mean FeNO values in adult patients with
asthma [45].
Most reports and meta-analyses of asthma management
have suggested that avoidance of indoor allergen exposure
is not of benefit and should not be recommended as a com-
ponent of asthma management [2,7,10]. However, here
we measured Der 1 levels by using a sensitive (1 pg/mL)
fluorometric ELISA. Also, it is usual to collect dust samples
by vacuuming and to calculate Der 1 levels as micrograms
of allergen per gram of dust [1,2,4,27,46]. Instead, we col-
lected dust samples in open Petri dishes and on adhesive
tape and detected a few Der 1 level by ELISA above de-
scribed. We consider that our assay and collection modes
were superior to those used in earlier studies; this is likely
the reason why reductions in allergen levels were reflected
in improved clinical outcomes.
Der p and Der f–specific IgE levels are correlated with
allergen exposure among sensitized participants [47]. In-
terventions that reduce exposure of child asthmatics to
HDMs cause the levels of both specific [44,48] and total
IgE [49] to fall.
We found, however, that the levels of Der p 1–specific
IgE measured with the CAP system fell between 2009
and 2010 in both the intervention and the control group.
Thus, reducing the level of exposure to Der 1 did not
affect the serum concentration of Der p 1–specific IgE.
We consider that the observed fall in reactive IgE levels
was attributable to the fact that all patients were treated
more intensively (including with ICS) in the interval be-
tween the two test periods than was the case before the
2009 test period.
We conclude that precise measurement of ambient
Der 1 levels by using a sensitive fluorometric ELISA may
be useful in the clinical management of asthma. Also,
encasing pillows and mattresses or futons in covers made
of microfine fibers and avoiding Der 1 exposure by using
an indoor hygiene protocol [4,27] may be of value in adult
asthma management.
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